RVNC Revance Therapeutics Inc: מכפיל מחיר להכנסות עתידי

The injectables market is protected by toxin purification patents and a strong brand. The forward price-to-sales ratio for Revance Therapeutics (RVNC) shows a pivot driven by expansion into spasticity therapy and a bet on the longevity of Daxxify, while strictly adhering to FDA regulations on biomaterial disposal. The current level is 1.50, which captures investors' real-time assessment of the company's future revenues.

Forward P/S measures the market value of a business relative to expected revenue, allowing for an assessment of whether an asset's price is overextended relative to future cash flows. Analyzing the forward P/S chart for Revance Therapeutics (RVNC) helps identify liquidity risks, as the aggressive scaling of the aesthetic injections distribution network requires colossal promotional expenditures, which temporarily offsets operating leverage and limits profitability.